Journal article

The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients

L Meyer, P Bohme, I Delbachian, P Lehert, N Cugnardey, P Drouin, B Guerci

DIABETES CARE | AMER DIABETES ASSOC | Published : 2002

Abstract

OBJECTIVE: This study was designed to assess the insulin-sparing effect of oral administration of metformin along with a continuous subcutaneous insulin infusion (CSII) for the treatment of type 1 diabetic patients. RESEARCH DESIGN AND METHODS: A total of 62 patients (25 women and 37 men) were studied in a monocenter, randomized, double-blind placebo-controlled study, comparing metformin (850 mg b.i.d.) with placebo in association with CSII during a 6-month period. RESULTS: Treatment with metformin was associated with a reduction in daily insulin requirements between V0 and V6 of -4.3 +/- 9.9 units (-7.8 +/- 18%) compared with an increase with placebo treatment of 1.7 +/- 8.3 units (2.8 +/- ..

View full abstract